Vermillion to File Ovarian Tumor Triage Panel Within Next Few Months | GenomeWeb
NEW YORK (GenomeWeb News) – Vermillion said today that its Ovarian Tumor Triage Test met its primary endpoints in a clinical study, and the firm will file for US Food and Drug Administration clearance of the test during the first half of this year, a company spokesperson told GenomeWeb Daily News.
 
The test is designed to stratify women with pelvic masses into high-risk and low-risk categories to help determine if they should be referred to a specialist prior to surgery.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.